Oberland Capital

Oberland Capital is a private investment firm dedicated to funding innovation in the global healthcare industry. With approximately $3 billion in assets under management, the firm specializes in flexible investment structures tailored to meet the specific needs of its partners. Oberland Capital offers a broad range of creative financing solutions, including the monetization of royalty streams, acquisition of future product revenues, project-based financing structures, and investments in traditional debt and equity.

The firm is committed to accelerating the development and commercialization of promising healthcare products to create value for its partners and transform patient care. Founded in 2013, Oberland Capital has a team of 25 professionals with deep industry knowledge and extensive structured finance experience. The firm's strategic approach includes working collaboratively with management teams to develop flexible, long-term structures that meet their specific strategic and financial objectives, deploying innovative structures tailored to the specifics of each geography, and providing meaningful amounts of capital—ranging from $50 million to over $300 million—to accelerate growth opportunities. Oberland Capital's portfolio includes investments in companies such as ClearPoint Neuro, Biohaven Pharmaceutical, and Verastem Oncology.

The firm has a global reach, with substantial transactional experience across the United States, Europe, and other territories, enabling it to deploy innovative structures tailored to the specifics of each geography. Oberland Capital's deep domain expertise, combined with its comprehensive understanding of investment structures and extensive experience in the United States, Europe, and other territories, allows it to effectively identify and execute transactions across the globe.

The firm's meaningful scale provides partners with significant amounts of capital to accelerate organic and inorganic growth opportunities. Oberland Capital's investment requirements include a focus on the pharmaceutical, biotechnology, medical device, and diagnostic industries, with a preference for companies in late-stage clinical development or under review by regulatory authorities.

The firm seeks to provide capital to biopharmaceutical, diagnostic, and medical device companies advancing products in late-stage clinical development or under review by regulatory authorities in exchange for royalties on the products once approved and commercialized. Oberland Capital's team members include Jean-Pierre Naegeli, Managing Partner; Andrew Rubinstein, Managing Partner; Cecilia Gonzalo, Partner; David Dubinsky, Chief Financial Officer; and James James, Managing Director, Business Development and Investor Relations.